Influenza A Virus, H5N1 Subtype Infections – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Influenza A Virus, H5N1 Subtype Infections – Pipeline Review, H1 2017’, provides an overview of the Influenza A Virus, H5N1 Subtype Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections

– The report reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Influenza A Virus, H5N1 Subtype Infections therapeutics and enlists all their major and minor projects

– The report assesses Influenza A Virus, H5N1 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akshaya Bio Inc

Altimmune Inc

Antigen Express Inc

Aphios Corp

BioDiem Ltd

BiondVax Pharmaceuticals Ltd

CEL-SCI Corp

Cocrystal Pharma Inc

Curevac AG

Fab'entech SA

Gemmus Pharma Inc

GlaxoSmithKline Plc

Hemispherx Biopharma Inc

iBio Inc

Inovio Pharmaceuticals Inc

Johnson & Johnson

Kineta Inc

Lakewood-Amedex Inc

Medicago Inc

Medigen Vaccine Biologics Corp

Microbiotix Inc

NanoBio Corp

Nanotherapeutics Inc

NanoViricides Inc

NewLink Genetics Corp

OPKO Health Inc

PaxVax Inc

PeptiDream Inc

Shionogi & Co Ltd

Takeda Pharmaceutical Company Ltd

TechnoVax Inc

TGV-Inhalonix Inc

Vaxart Inc

Vaxine Pty Ltd

VaxInnate Corp

Visterra Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Influenza A Virus, H5N1 Subtype Infections Overview 8

Influenza A Virus, H5N1 Subtype Infections Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 19

Influenza A Virus, H5N1 Subtype Infections Therapeutics Assessment 20

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Influenza A Virus, H5N1 Subtype Infections Companies Involved in Therapeutics Development 28

Akshaya Bio Inc 28

Altimmune Inc 28

Antigen Express Inc 29

Aphios Corp 29

BioDiem Ltd 30

BiondVax Pharmaceuticals Ltd 30

CEL-SCI Corp 31

Cocrystal Pharma Inc 31

Curevac AG 32

Fab'entech SA 32

Gemmus Pharma Inc 33

GlaxoSmithKline Plc 33

Hemispherx Biopharma Inc 34

iBio Inc 34

Inovio Pharmaceuticals Inc 35

Johnson & Johnson 35

Kineta Inc 36

Lakewood-Amedex Inc 36

Medicago Inc 37

Medigen Vaccine Biologics Corp 37

Microbiotix Inc 38

NanoBio Corp 38

Nanotherapeutics Inc 39

NanoViricides Inc 39

NewLink Genetics Corp 40

OPKO Health Inc 40

PaxVax Inc 41

PeptiDream Inc 41

Shionogi & Co Ltd 42

Takeda Pharmaceutical Company Ltd 43

TechnoVax Inc 43

TGV-Inhalonix Inc 44

Vaxart Inc 44

Vaxine Pty Ltd 45

VaxInnate Corp 45

Visterra Inc 46

Influenza A Virus, H5N1 Subtype Infections Drug Profiles 47

AE-AI vaccine Drug Profile 47

Alferon LDO Drug Profile 48

APP-0205 Drug Profile 50

APP-309 Drug Profile 51

AT-301 Drug Profile 52

CC-42344 Drug Profile 53

CEL-1000 Drug Profile 54

CHOS-05 Drug Profile 56

DPC-005 Drug Profile 57

FBF-001 Drug Profile 58

Gamma-Flu Drug Profile 59

GP-1001 Drug Profile 60

GP-1002 Drug Profile 61

GP-1681 Drug Profile 62

GREFLU/VIE Drug Profile 64

HAI-05 Drug Profile 65

HB-36.6 Drug Profile 67

Influ-nRNA Drug Profile 68

influenza [strain A/H5N1] (split virion) vaccine Drug Profile 69

influenza [strain A/H5N1] (virus like particle) vaccine 2 Drug Profile 70

influenza [strain A/H5N1] vaccine Drug Profile 73

influenza [strain A/H5N1] vaccine Drug Profile 74

influenza [strain A/H5N1] vaccine Drug Profile 75

influenza [strain A/H5N1] vaccine Drug Profile 77

influenza [strain A/H5N1] vaccine Drug Profile 78

influenza [strain A/H5N1] vaccine Drug Profile 79

influenza [strain A/H5N1] vaccine Drug Profile 80

influenza [strain A/H5N1] vaccine Drug Profile 81

influenza [strain A/H5N1] vaccine Drug Profile 82

influenza [strain A/H5N1] vaccine 2 Drug Profile 83

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine Drug Profile 84

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine Drug Profile 85

influenza [strains A/H1N1 + A/H5N1] vaccine Drug Profile 86

influenza [strains A/H5N1 + A/H1N1] vaccine Drug Profile 87

influenza [strains A/H5N1 + A/H7N2 + A/H9N2 + A/H7N3 + A/ H5N2] (virus like particle) vaccine Drug Profile 88

influenza vaccine Drug Profile 89

INO-3510 Drug Profile 91

JNJ-3872 Drug Profile 93

KD-295 Drug Profile 96

KIN-1148 Drug Profile 98

Lalistat Drug Profile 100

M-001 Drug Profile 101

MBX-2329 Drug Profile 107

MBX-2546 Drug Profile 108

Monoclonal Antibodies to Inhibit Hemagglutinin for Avian Infection and Swine Flu Infection Drug Profile 109

Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza Infections Drug Profile 110

MV-4 Drug Profile 111

Nasovax Drug Profile 112

NVINF-1 Drug Profile 114

NVINF-2 Drug Profile 119

OrniFlu Drug Profile 122

PD-001 Drug Profile 123

Peptides for Influenza Infections Drug Profile 124

PNSIA-28 Drug Profile 125

PNSIA-49 Drug Profile 126

PXVX-0103 Drug Profile 127

rintatolimod Drug Profile 129

S-033188 Drug Profile 139

Small Molecules for Influenza A Virus H1N1 and H5N1 Infections Drug Profile 141

Small Molecules to Activate Sirtuin for Influenza Drug Profile 142

Synthetic Peptides for Influenza, HSV and HIV Infections Drug Profile 143

Synthetic Peptides for Viral Infections Drug Profile 144

TVX-003 Drug Profile 145

VAX-161C Drug Profile 146

VGX-3400X Drug Profile 147

VH-244 Drug Profile 149

VIS-410 Drug Profile 150

Influenza A Virus, H5N1 Subtype Infections Dormant Projects 153

Influenza A Virus, H5N1 Subtype Infections Discontinued Products 156

Influenza A Virus, H5N1 Subtype Infections Product Development Milestones 157

Featured News & Press Releases 157

Appendix 167

Methodology 167

Coverage 167

Secondary Research 167

Primary Research 167

Expert Panel Validation 167

Contact Us 167

Disclaimer 168

List of Tables

List of Tables

Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Akshaya Bio Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Altimmune Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Antigen Express Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Aphios Corp, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by BioDiem Ltd, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by BiondVax Pharmaceuticals Ltd, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by CEL-SCI Corp, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Cocrystal Pharma Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Curevac AG, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Fab'entech SA, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Gemmus Pharma Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by GlaxoSmithKline Plc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Hemispherx Biopharma Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by iBio Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Johnson & Johnson, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Kineta Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Lakewood-Amedex Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Medicago Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Medigen Vaccine Biologics Corp, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Microbiotix Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by NanoBio Corp, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Nanotherapeutics Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by NanoViricides Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by NewLink Genetics Corp, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by OPKO Health Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by PaxVax Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by PeptiDream Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Shionogi & Co Ltd, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by TechnoVax Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by TGV-Inhalonix Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Vaxart Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Vaxine Pty Ltd, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by VaxInnate Corp, H1 2017

Influenza A Virus, H5N1 Subtype Infections Pipeline by Visterra Inc, H1 2017

Influenza A Virus, H5N1 Subtype Infections Dormant Projects, H1 2017

Influenza A Virus, H5N1 Subtype Infections Dormant Projects, H1 2017 (Contd..1), H1 2017

Influenza A Virus, H5N1 Subtype Infections Dormant Projects, H1 2017 (Contd..2), H1 2017

Influenza A Virus, H5N1 Subtype Infections Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports